Compass Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Compass Therapeutics (CMPX).

Price Target Range — 11 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

13Buy

1Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$9Upside to Avg. PT+1033.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Craig-Hallum	Albert Lowe	PT Cut	Buy	$15→$8
Sep 23, 2026	Citizens	Reni J. Benjamin	PT Cut	Market Outperform	$10→$4
Sep 23, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$8→$4
Sep 23, 2026	Wedbush	Robert Driscoll	Downgrade	Outperform→Neutral	$5→$1
Sep 23, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$24→$12
Aug 7, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$4→$6
Apr 28, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$13→$7
Apr 28, 2026	Citizens	Reni J. Benjamin	Maintained	Market Outperform	$10
Apr 27, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$24
Apr 27, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$30
Mar 24, 2026	Guggenheim	Michael Schmidt	Maintained	Buy	$12
Jan 6, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$30
Jan 5, 2026	William Blair	Matt Phipps	Initiate	Outperform	—
Dec 3, 2025	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
Dec 3, 2025	Citizens	Reni Benjamin	Initiate	Market Outperform	$10
Dec 3, 2025	Canaccord Genuity	John Newman	Initiate	Buy	$10
Nov 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$30
Oct 6, 2025	LifeSci Capital	—	Initiate	Outperform	$10
Aug 12, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$32
Aug 12, 2025	Guggenheim	Michael Schmidt	PT Raise	Buy	$10→$12

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.

Avi Kapoor

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

Craig-Hallum analyst Albert Lowe maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $15 to $8.

Benzinga Newsdesk

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.

Avi Kapoor

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

Citizens analyst Reni J. Benjamin maintains Compass Therapeutics (NASDAQ:CMPX) with a Market Outperform and lowers the price target from $10 to $4.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

Guggenheim analyst Michael Schmidt maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $8 to $4.

Benzinga Newsdesk

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.

Benzinga Newsdesk

Compass Therapeutics Inc

Compass Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

People Also Watch

People Also Watch

Compass Therapeutics Inc

Compass Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

PROCraig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PROCitizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

PROGuggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

PROWedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1

People Also Watch

People Also Watch

PRO
Craig-Hallum Maintains Buy on Compass Therapeutics, Lowers Price Target to $8

PRO
Citizens Maintains Market Outperform on Compass Therapeutics, Lowers Price Target to $4

PRO
Guggenheim Maintains Buy on Compass Therapeutics, Lowers Price Target to $4

PRO
Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1